Lexicon Pharmaceuticals Enters Into Agreement With TerSera Therapeutics for the Sale of XERMELO

    NEXT STORY
    Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program
    PREV STORY
    QuestCap Secures Exclusive Sales Rights for Emergency Use Authorized COVID-19 Lateral Flow Antibody Test Kit
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Helsinn Group Announces First Patient Enrolled in Phase 3b Study of NEPA IV vs NEPA Oral for the prevention of chemotherapy induced nausea and vomiting (CINV) in Women with Breast Cancer

    Lugano, Switzerland, March 20, 2018 - Helsinn, a Swiss pharmaceutical group focused on building ...

    author_avatar
    NASDAQ Market News

    10x Genomics to Report First Quarter Financial Results on May 11, 2020

    author_avatar
    NASDAQ Market News

    Aladote® is concluded as safe in first clinical study – PledPharma aims to apply for Orphan Drug Status in the US

    Today PledPharma (publ) announces that the company has received a positive conclusion of the ...

    author_avatar
    NASDAQ Market News